These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 8980763

  • 1. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
    Clement JJ, Tanaka SK, Alder J, Vojtko C, Beyer J, Hensey D, Ramer N, McDaniel D, Chu DT.
    Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A, Petersen U, Endermann R.
    Chemotherapy; 1996 May; 42(6):410-25. PubMed ID: 8957575
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA, García Sánchez JE, García García MI, Fresnadillo MJ, Trujillano I, García Sánchez E.
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP, Hoogkamp-Korstanje JA.
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [Abstract] [Full Text] [Related]

  • 6. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D.
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [Abstract] [Full Text] [Related]

  • 7. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC, Chin NX.
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
    Marshall SA, Jones RN.
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2747-53. PubMed ID: 8109948
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
    Tanaka M, Hoshino K, Ishida H, Sato K, Hayakawa I, Osada Y.
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
    [Abstract] [Full Text] [Related]

  • 11. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R, Brenwald NP, Andrews JM, Boswell F.
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
    Souli M, Wennersten CB, Eliopoulos GM.
    Int J Antimicrob Agents; 1998 Apr; 10(1):23-30. PubMed ID: 9624540
    [Abstract] [Full Text] [Related]

  • 14. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS, Mazens-Sullivan MF, Bartlett RC.
    Chemotherapy; 1992 Apr; 38(5):308-18. PubMed ID: 1337507
    [Abstract] [Full Text] [Related]

  • 15. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 16. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
    Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P.
    Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
    [Abstract] [Full Text] [Related]

  • 17. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R, Andrews JM, Brenwald N.
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ, Baskerville AJ, Sanghrajka M, Mumtaz G, Felmingham D, Ridgway GL, Grüneberg RN.
    Diagn Microbiol Infect Dis; 1989 Jan; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
    Chin NX, Neu HC.
    J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
    [Abstract] [Full Text] [Related]

  • 20. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.